PPARG and type 2 diabetes mellitus: From metabolic disease, the resolution of insulin resistance by PPARγ and combined PPARα/γ agonists, as well as long-term outcome in patients with type II diabetes, we learned a lot on simultaneous PPARα/γ stimulation.